{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T16:40:40Z","timestamp":1770482440278,"version":"3.49.0"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2010,3,9]],"date-time":"2010-03-09T00:00:00Z","timestamp":1268092800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1038\/nrurol.2010.24","type":"journal-article","created":{"date-parts":[[2010,3,9]],"date-time":"2010-03-09T10:55:54Z","timestamp":1268132154000},"page":"215-221","source":"Crossref","is-referenced-by-count":75,"title":["Treatment of Peyronie's disease with PDE5 inhibitors: an antifibrotic strategy"],"prefix":"10.1038","volume":"7","author":[{"given":"Nestor F.","family":"Gonzalez-Cadavid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Rajfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,3,9]]},"reference":[{"key":"BFnrurol201024_CR1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-1-59745-161-1_3","volume-title":"Current Clinical Urology: Peyronie's Disease, A Guide to Clinical Management","author":"NF Gonzalez-Cadavid","year":"2007","unstructured":"Gonzalez-Cadavid, N. F. & Rajfer, J. in Current Clinical Urology: Peyronie's Disease, A Guide to Clinical Management (ed. Levine, L. A. ) 19\u201339 (Humana Press, Totowa, 2007)."},{"key":"BFnrurol201024_CR2","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/ijir.2008.30","volume":"20","author":"JF Smith","year":"2008","unstructured":"Smith, J. F., Walsh, T. J. & Lue, T. F. Peyronie's disease: a critical appraisal of current diagnosis and treatment. Int. J. Impot. Res. 20, 445\u2013459 (2008).","journal-title":"Int. J. Impot. Res."},{"key":"BFnrurol201024_CR3","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1111\/j.1743-6109.2008.01081.x","volume":"6","author":"A M\u00fcller","year":"2009","unstructured":"M\u00fcller, A. & Mulhall, J. P. Peyronie's disease intervention trials: methodological challenges and issues. J. Sex. Med. 6, 848\u2013861 (2009).","journal-title":"J. Sex. Med."},{"key":"BFnrurol201024_CR4","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/j.1464-410X.2005.05391.x","volume":"95","author":"CJ Smith","year":"2005","unstructured":"Smith, C. J., McMahon, C. & Shabsigh, R. Peyronie's disease: the epidemiology, aetiology and clinical evaluation of deformity. BJU Int. 95, 729\u2013732 (2005).","journal-title":"BJU Int."},{"key":"BFnrurol201024_CR5","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1097\/01.ju.0000127744.18878.f1","volume":"171","author":"JP Mulhall","year":"2004","unstructured":"Mulhall, J. P. et al. Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening. J. Urol. 171, 2350\u20132353 (2004).","journal-title":"J. Urol."},{"key":"BFnrurol201024_CR6","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.ucl.2007.08.017","volume":"34","author":"FL Taylor","year":"2007","unstructured":"Taylor, F. L. & Levine, L. A. Peyronie's disease. Urol. Clin. North Am. 34, 517\u2013534 (2007).","journal-title":"Urol. Clin. North Am."},{"key":"BFnrurol201024_CR7","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S0895-4356(98)00015-8","volume":"51","author":"MP Carrieri","year":"1998","unstructured":"Carrieri, M. P., Serraino, D., Palmiotto, F., Nucci, G. & Sasso, F. A case\u2013control study on risk factors for Peyronie's disease. J. Clin. Epidemiol. 51, 511\u2013515 (1998).","journal-title":"J. Clin. Epidemiol."},{"key":"BFnrurol201024_CR8","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/j.1743-6109.2006.00344.x","volume":"4","author":"S Deveci","year":"2007","unstructured":"Deveci, S. et al. Defining the clinical characteristics of Peyronie's disease in young men. J. Sex. Med. 4, 485\u2013490 (2007).","journal-title":"J. Sex. Med."},{"key":"BFnrurol201024_CR9","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1111\/j.1464-410X.2006.05969.x","volume":"97","author":"MD Bjekic","year":"2006","unstructured":"Bjekic, M. D., Vlajinac, H. D., Sipetic, S. B. & Marinkovic, J. M. Risk factors for Peyronie's disease: a case\u2013control study. BJU Int. 97, 570\u2013574 (2006).","journal-title":"BJU Int."},{"key":"BFnrurol201024_CR10","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1743-6109.2008.01104.x","volume":"6","author":"NF Gonzalez-Cadavid","year":"2009","unstructured":"Gonzalez-Cadavid, N. F. & Rajfer, J. Experimental models of Peyronie's disease. Implications for new therapies. J. Sex. Med. 6, 303\u2013313 (2009).","journal-title":"J. Sex. Med."},{"key":"BFnrurol201024_CR11","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.niox.2003.12.002","volume":"9","author":"EG Valente","year":"2003","unstructured":"Valente, E. G. et al. L-Arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures. Nitric Oxide 9, 229\u2013244 (2003).","journal-title":"Nitric Oxide"},{"key":"BFnrurol201024_CR12","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S0022-5347(01)65361-8","volume":"157","author":"CJ Devine Jr","year":"1997","unstructured":"Devine, C. J. Jr, Somers, K. D., Jordan, S. G. & Schlossberg, S. M. Proposal: trauma as the cause of the Peyronie's lesion. J. Urol. 157, 285\u2013290 (1997).","journal-title":"J. Urol."},{"key":"BFnrurol201024_CR13","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S0022-5347(01)65367-9","volume":"157","author":"KD Somers","year":"1997","unstructured":"Somers, K. D. & Dawson, D. M. Fibrin deposition in Peyronie's disease plaque. J. Urol. 157, 311\u2013315 (1997).","journal-title":"J. Urol."},{"key":"BFnrurol201024_CR14","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.urology.2005.01.010","volume":"65","author":"HH Davila","year":"2005","unstructured":"Davila, H. H., Magee, T. R., Zuniga, F. I., Rajfer, J. & Gonzalez-Cadavid, N. F. Peyronie's disease associated with increase in plasminogen activator inhibitor in fibrotic plaque. Urology 65, 645\u2013648 (2005).","journal-title":"Urology"},{"key":"BFnrurol201024_CR15","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1046\/j.1464-410X.2003.04224.x","volume":"91","author":"HH Davila","year":"2003","unstructured":"Davila, H. H., Ferrini, M. G., Rajfer, J. & Gonzalez-Cadavid, N. F. Fibrin as an inducer of fibrosis in the tunica albuginea of the rat: a new animal model of Peyronie's disease. BJU Int. 91, 830\u2013838 (2003).","journal-title":"BJU Int."},{"key":"BFnrurol201024_CR16","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/S0022-5347(01)65368-0","volume":"157","author":"HP Ehrlich","year":"1997","unstructured":"Ehrlich, H. P. Scar contracture: cellular and connective tissue aspects in Peyronie's disease. J. Urol. 157, 316\u2013319 (1997).","journal-title":"J. Urol."},{"key":"BFnrurol201024_CR17","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1095\/biolreprod.104.030833","volume":"71","author":"HH Davila","year":"2004","unstructured":"Davila, H. H., Magee, T. R., Vernet, D., Rajfer, J. & Gonzalez-Cadavid, N. F. Gene transfer of inducible nitric oxide synthase complementary DNA regresses the fibrotic plaque in an animal model of Peyronie's disease. Biol. Reprod. 71, 1568\u20131577 (2004).","journal-title":"Biol. Reprod."},{"key":"BFnrurol201024_CR18","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1097\/01.ju.0000097498.34847.7c","volume":"171","author":"MF Usta","year":"2004","unstructured":"Usta, M. F. et al. Relationship between the severity of penile curvature and the presence of comorbidities in men with Peyronie's disease. J. Urol. 171, 775\u2013779 (2004).","journal-title":"J. Urol."},{"key":"BFnrurol201024_CR19","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1023\/A:1014485204205","volume":"32","author":"P Perimenis","year":"2001","unstructured":"Perimenis, P., Athanasopoulos, A., Gyftopoulos, K., Katsenis, G. & Barbalias, G. Peyronie's disease: epidemiology and clinical presentation of 134 cases. Int. Urol. Nephrol. 32, 691\u2013694 (2001).","journal-title":"Int. Urol. Nephrol."},{"key":"BFnrurol201024_CR20","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1097\/00005392-199805000-00097","volume":"159","author":"AI El-Sakka","year":"1998","unstructured":"El-Sakka, A. I., Selph, C. A., Yen, T. S., Dahiya, R. & Lue, T. F. The effect of surgical trauma on rat tunica albuginea. J. Urol. 159, 1700\u20131707 (1998).","journal-title":"J. Urol."},{"key":"BFnrurol201024_CR21","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/S0090-4295(97)00333-6","volume":"50","author":"D Schiavino","year":"1997","unstructured":"Schiavino, D. et al. Immunologic findings in Peyronie's disease: a controlled study. Urology 50, 764\u2013768 (1997).","journal-title":"Urology"},{"issue":"Suppl. 4","key":"BFnrurol201024_CR22","doi-asserted-by":"publisher","first-page":"S127","DOI":"10.1038\/sj.ijir.3900591","volume":"12","author":"MB Noss","year":"2000","unstructured":"Noss, M. B., Day, N. S., Christ, G. J. & Melman, A. The genetics and immunology of Peyronie's disease. Int. J. Impot. Res. 12 (Suppl. 4), S127\u2013S132 (2000).","journal-title":"Int. J. Impot. Res."},{"key":"BFnrurol201024_CR23","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1097\/01.ju.0000076488.89748.e1","volume":"170","author":"EW Hauck","year":"2003","unstructured":"Hauck, E. W., Hauptmann, A., Weidner, W., Bein, G. & Hackstein, H. Prospective analysis of HLA classes I and II antigen frequency in patients with Peyronie's disease. J. Urol. 170, 1443\u20131446 (2003).","journal-title":"J. Urol."},{"key":"BFnrurol201024_CR24","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/BF02768246","volume":"26","author":"K Anafarta","year":"1994","unstructured":"Anafarta, K., Bed\u00fck, Y., Uluoglu, O., Aydos, K. & Baltaci, S. The significance of histopathological changes of the normal tunica albuginea in Peyronie's disease. Int. Urol. Nephrol. 26, 71\u201377 (1994).","journal-title":"Int. Urol. Nephrol."},{"key":"BFnrurol201024_CR25","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1006\/niox.2001.0421","volume":"6","author":"MG Ferrini","year":"2002","unstructured":"Ferrini, M. G. et al. Antifibrotic role of inducible nitric oxide synthase. Nitric Oxide 6, 283\u2013294 (2002).","journal-title":"Nitric Oxide"},{"key":"BFnrurol201024_CR26","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.2353\/ajpath.2007.070112","volume":"170","author":"B Hinz","year":"2007","unstructured":"Hinz, B. et al. The myofibroblast: one function, multiple origins. Am. J. Pathol. 170, 1807\u20131816 (2007).","journal-title":"Am. J. Pathol."},{"key":"BFnrurol201024_CR27","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1111\/j.1582-4934.2007.00213.x","volume":"12","author":"B Eyden","year":"2008","unstructured":"Eyden, B. The myofibroblast: phenotypic characterization as a prerequisite to understanding its functions in translational medicine. J. Cell. Mol. Med. 12, 2022\u20132037 (2008).","journal-title":"J. Cell. Mol. Med."},{"key":"BFnrurol201024_CR28","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/S0022-5347(17)53917-8","volume":"127","author":"KD Somers","year":"1982","unstructured":"Somers, K. D. et al. Cell culture of Peyronie's disease plaque and normal penile tissue. J. Urol. 127, 585\u2013588 (1982).","journal-title":"J. Urol."},{"key":"BFnrurol201024_CR29","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/sj.ijir.3900874","volume":"14","author":"JP Mulhall","year":"2002","unstructured":"Mulhall, J. P., Anderson, M. S., Lubrano, T. & Shankey, T. V. Peyronie's disease cell culture models: phenotypic, genotypic and functional analyses. Int. J. Impot. Res. 14, 397\u2013405 (2002).","journal-title":"Int. J. Impot. Res."},{"key":"BFnrurol201024_CR30","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S1089-8603(02)00124-6","volume":"7","author":"D Vernet","year":"2002","unstructured":"Vernet, D. et al. Effect of nitric oxide on the differentiation of fibroblasts into myofibroblasts in the Peyronie's fibrotic plaque and in its rat model. Nitric Oxide 7, 262\u2013276 (2002).","journal-title":"Nitric Oxide"},{"key":"BFnrurol201024_CR31","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1095\/biolreprod.105.041038","volume":"73","author":"D Vernet","year":"2005","unstructured":"Vernet, D. et al. Evidence that osteogenic progenitor cells in the human tunica albuginea may originate from stem cells: implications for peyronie disease. Biol. Reprod. 73, 1199\u20131210 (2005).","journal-title":"Biol. Reprod."},{"key":"BFnrurol201024_CR32","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/j.1743-6109.2005.00197.x","volume":"3","author":"D Vernet","year":"2006","unstructured":"Vernet, D. et al. Phosphodiesterase type 5 is not upregulated by tadalafil in cultures of human penile cells. J. Sex. Med. 3, 84\u201394 (2006).","journal-title":"J. Sex. Med."},{"key":"BFnrurol201024_CR33","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/S0022-5347(17)53599-5","volume":"127","author":"JS Vande Berg","year":"1982","unstructured":"Vande Berg, J. S. et al. Mechanisms of calcification in Peyronie's disease. J. Urol. 127, 52\u201354 (1982).","journal-title":"J. Urol."},{"key":"BFnrurol201024_CR34","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S0022-5347(05)64578-8","volume":"168","author":"A Kadioglu","year":"2002","unstructured":"Kadioglu, A. et al. A retrospective review of 307 men with Peyronie's disease. J. Urol. 168, 1075\u20131079 (2002).","journal-title":"J. Urol."},{"key":"BFnrurol201024_CR35","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/path.2277","volume":"214","author":"TA Wynn","year":"2008","unstructured":"Wynn, T. A. Cellular and molecular mechanisms of fibrosis. J. Pathol. 214, 199\u2013210 (2008).","journal-title":"J. Pathol."},{"key":"BFnrurol201024_CR36","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1016\/S0022-5347(01)64223-X","volume":"158","author":"AI El-Sakka","year":"1997","unstructured":"El-Sakka, A. I., Hassoba, H. M., Pillarisetty, R. J., Dahiya, R. & Lue, T. F. Peyronie's disease is associated with an increase in transforming growth factor-beta protein expression. J. Urol. 158, 1391\u20131394 (1997).","journal-title":"J. Urol."},{"key":"BFnrurol201024_CR37","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/S0022-5347(01)68236-3","volume":"158","author":"AI El-Sakka","year":"1997","unstructured":"El-Sakka, A. I. et al. An animal model of Peyronie's-like condition associated with an increase of transforming growth factor beta mRNA and protein expression. J. Urol. 158, 2284\u20132290 (1997).","journal-title":"J. Urol."},{"key":"BFnrurol201024_CR38","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1046\/j.1464-410x.1998.00529.x","volume":"81","author":"AI El-Sakka","year":"1998","unstructured":"El-Sakka, A. I. et al. Histological and ultrastructural alterations in an animal model of Peyronie's disease. Br. J. Urol. 81, 445\u2013452 (1998).","journal-title":"Br. J. Urol."},{"key":"BFnrurol201024_CR39","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1016\/S0022-5347(05)67616-1","volume":"163","author":"TJ Bivalacqua","year":"2000","unstructured":"Bivalacqua, T. J. et al. A rat model of Peyronie's disease associated with a decrease in erectile activity and an increase in inducible nitric oxide synthase protein expression. J. Urol. 163, 1992\u20131998 (2000).","journal-title":"J. Urol."},{"key":"BFnrurol201024_CR40","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/j.1464-410X.2006.05955.x","volume":"97","author":"MG Ferrini","year":"2006","unstructured":"Ferrini, M. G., Kovanecz, I., Nolazco, G., Rajfer, J. & Gonzalez-Cadavid, N. F. Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease. BJU Int. 97, 625\u2013633 (2006).","journal-title":"BJU Int."},{"key":"BFnrurol201024_CR41","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1111\/j.1743-6109.2008.00847.x","volume":"5","author":"LP Cantini","year":"2008","unstructured":"Cantini, L. P. et al. Profibrotic role of myostatin in Peyronie's disease. J. Sex. Med. 5, 1607\u20131622 (2008).","journal-title":"J. Sex. Med."},{"key":"BFnrurol201024_CR42","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/j.1365-2605.2007.00780.x","volume":"31","author":"S Piao","year":"2008","unstructured":"Piao, S. et al. Repeated intratunical injection of adenovirus expressing transforming growth factor-\u03b21 in a rat induces penile curvature with tunical fibrotic plaque: a useful model for the study of Peyronie's disease. Int. J. Androl. 31, 346\u2013353 (2008).","journal-title":"Int. J. Androl."},{"key":"BFnrurol201024_CR43","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/j.1743-6109.2005.00090.x","volume":"3","author":"J Rajfer","year":"2006","unstructured":"Rajfer, J., Gore, J. L., Kaufman, J. & Gonzalez-Cadavid, N. Case report: avoidance of palpable corporal fibrosis due to priapism with upregulators of nitric oxide. J. Sex. Med. 3, 173\u2013176 (2006).","journal-title":"J. Sex. Med."},{"key":"BFnrurol201024_CR44","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1016\/j.biocel.2008.05.012","volume":"40","author":"M Lucattelli","year":"2008","unstructured":"Lucattelli, M. et al. A new mouse model of Peyronie's disease: an increased expression of hypoxia-induciblefactor-1 target genes during the development of penile changes. Int. J. Biochem. Cell Biol. 40, 2638\u20132648 (2008).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"BFnrurol201024_CR45","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1111\/j.1464-410X.2008.07507.x","volume":"101","author":"G Nolazco","year":"2008","unstructured":"Nolazco, G. et al. Effect of muscle-derived stem cells on the restoration of corpora cavernosa smooth muscle and erectile function in the aged rat. BJU Int. 101, 1156\u20131164 (2008).","journal-title":"BJU Int."},{"issue":"Suppl. 5","key":"BFnrurol201024_CR46","doi-asserted-by":"publisher","first-page":"S93","DOI":"10.1038\/sj.ijir.3901082","volume":"15","author":"JP Mulhall","year":"2003","unstructured":"Mulhall, J. P. Expanding the paradigm for plaque development in Peyronie's disease. Int. J. Impot. Res. 15 (Suppl. 5), S93\u2013S102 (2003).","journal-title":"Int. J. Impot. Res."},{"key":"BFnrurol201024_CR47","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/sj.ijir.3901183","volume":"16","author":"JP Mulhall","year":"2004","unstructured":"Mulhall, J. P. et al. Peyronie's disease fibroblasts demonstrate tumorigenicity in the severe combined immunodeficient (SCID) mouse model. Int. J. Impot. Res. 16, 99\u2013104 (2004).","journal-title":"Int. J. Impot. Res."},{"key":"BFnrurol201024_CR48","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/ncpuro0201","volume":"2","author":"NF Gonzalez-Cadavid","year":"2005","unstructured":"Gonzalez-Cadavid, N. F. & Rajfer, J. Mechanisms of disease: new insights into the cellular and molecular pathology of Peyronie's disease. Nat. Clin. Pract. Urol. 2, 291\u2013297 (2005).","journal-title":"Nat. Clin. Pract. Urol."},{"issue":"Suppl. 3","key":"BFnrurol201024_CR49","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/j.1743-6109.2008.01195.x","volume":"6","author":"NF Gonzalez-Cadavid","year":"2009","unstructured":"Gonzalez-Cadavid, N. F. Mechanisms of penile fibrosis. J. Sex. Med. 6 (Suppl. 3), 353\u2013362 (2009).","journal-title":"J. Sex. Med."},{"key":"BFnrurol201024_CR50","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/9780470755235.ch14","volume-title":"Standard Practice in Sexual Medicine","author":"A Nehra","year":"2006","unstructured":"Nehra, A. & Nylhall, J. Peyronie's disease. In Standard Practice in Sexual Medicine 1st edn (eds Porst, H. & Buvat, J.) 158\u2013173 (Blackwell, Malden, 2006)."},{"issue":"Suppl. 5","key":"BFnrurol201024_CR51","doi-asserted-by":"publisher","first-page":"S93","DOI":"10.1038\/sj.ijir.3901082","volume":"15","author":"JP Mulhall","year":"2003","unstructured":"Mulhall, J. P. Expanding the paradigm for plaque development in Peyronie's disease. Int. J. Impot. Res. 15 (Suppl. 5), S93\u2013S102 (2003).","journal-title":"Int. J. Impot. Res."},{"key":"BFnrurol201024_CR52","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1016\/j.juro.2008.01.093","volume":"179","author":"M Del Carlo","year":"2008","unstructured":"Del Carlo, M., Cole, A. A. & Levine, L. A. Differential calcium independent regulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases by interleukin-1\u03b2 and transforming growth factor-\u03b2 in Peyronie's plaque fibroblasts. J. Urol. 179, 2447\u20132455 (2008).","journal-title":"J. Urol."},{"key":"BFnrurol201024_CR53","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0090-4295(01)01578-3","volume":"59","author":"TR Magee","year":"2002","unstructured":"Magee, T. R. et al. Gene expression profiles in the Peyronie's disease plaque. Urology 59, 451\u2013457 (2002).","journal-title":"Urology"},{"key":"BFnrurol201024_CR54","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.urology.2004.04.006","volume":"64","author":"A Qian","year":"2004","unstructured":"Qian, A., Meals, R. A., Rajfer, J. & Gonzalez-Cadavid, N. F. Comparison of gene expression profiles between Peyronie's disease and Dupuytren's contracture. Urology 64, 399\u2013404 (2004).","journal-title":"Urology"},{"key":"BFnrurol201024_CR55","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2164\/jandrol.108.006221","volume":"30","author":"W Hellstrom","year":"2009","unstructured":"Hellstrom, W. Medical management of Peyronie's disease. J. Androl. 30, 397\u2013404 (2009).","journal-title":"J. Androl."},{"key":"BFnrurol201024_CR56","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/s00011-008-7166-y","volume":"57","author":"P Sivakumar","year":"2008","unstructured":"Sivakumar, P. & Das, A. M. Fibrosis, chronic inflammation and new pathways for drug discovery. Inflamm. Res. 57, 410\u2013418 (2008).","journal-title":"Inflamm. Res."},{"key":"BFnrurol201024_CR57","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.2174\/138161205774913372","volume":"11","author":"NF Gonzalez-Cadavid","year":"2005","unstructured":"Gonzalez-Cadavid, N. F. & Rajfer, J. The pleiotropic effects of inducible nitric oxide synthase on the physiology and pathology of penile erection. Curr. Pharm. Des. 11, 4041\u20134046 (2005).","journal-title":"Curr. Pharm. Des."},{"key":"BFnrurol201024_CR58","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.cardiores.2003.12.006","volume":"61","author":"MG Ferrini","year":"2004","unstructured":"Ferrini, M. G., Davila, H., Valente, E. G., Gonzalez-Cadavid, N. F. & Rajfer, J. Aging-related induction of inducible nitric oxide synthase (iNOS) is vasculo-protective in the arterial media. Cardiovasc. Res. 61, 796\u2013805 (2004).","journal-title":"Cardiovasc. Res."},{"key":"BFnrurol201024_CR59","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.urology.2006.05.011","volume":"68","author":"MG Ferrini","year":"2006","unstructured":"Ferrini, M. G. et al. Long-term continuous treatment with vardenafil prevents fibrosis and preserves smooth muscle content in the rat corpora cavernosa after bilateral cavernosal nerve transection. Urology 68, 429\u2013435 (2006).","journal-title":"Urology"},{"key":"BFnrurol201024_CR60","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1095\/biolreprod.106.059642","volume":"76","author":"MG Ferrini","year":"2007","unstructured":"Ferrini, M. G. et al. Long-term continuous treatment with sildenafil ameliorates aging-related erectile dysfunction and the underlying corporal fibrosis in the rat. Biol. Reprod. 76, 915\u2013923 (2007).","journal-title":"Biol. Reprod."},{"key":"BFnrurol201024_CR61","first-page":"867","volume":"100","author":"I Kovanecz","year":"2007","unstructured":"Kovanecz, I. et al. Long term sildenafil treatment ameliorates corporal veno-occlusive dysfunction (CVOD) induced by cavernosal nerve resection in rats. Int. J. Impot. Res. 100, 867\u2013874 (2007).","journal-title":"Int. J. Impot. Res."},{"key":"BFnrurol201024_CR62","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1464-410X.2007.07223.x","volume":"101","author":"I Kovanecz","year":"2008","unstructured":"Kovanecz, I. et al. Chronic daily tadalafil prevents the corporal fibrosis and veno-occlusive dysfunction (CVOD) that occurs following cavernosal nerve resection in the rat. BJU Int. 101, 203\u2013210 (2008).","journal-title":"BJU Int."},{"key":"BFnrurol201024_CR63","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/j.1743-6109.2008.01105.x","volume":"6","author":"MG Ferrini","year":"2009","unstructured":"Ferrini, M. G. et al. Fibrosis and loss of smooth muscle in the corpora cavernosa precede corporal veno-occlusive dysfunction (CVOD) induced by experimental cavernosal nerve damage in the rat. J. Sex. Med. 6, 415\u2013428 (2009).","journal-title":"J. Sex. Med."},{"key":"BFnrurol201024_CR64","unstructured":"Ferrini, M. G. et al. The genetic inactivation of inducible nitric oxide synthase intensifies fibrosis and oxidative stress in the penile corpora cavernosa in type 1 diabetes. J. Sex. Med. (in press)."},{"key":"BFnrurol201024_CR65","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1038\/labinvest.3780182","volume":"80","author":"D Hochberg","year":"2000","unstructured":"Hochberg, D. et al. Interstitial fibrosis of unilateral ureteral obstruction is exacerbated in kidneys of mice lacking the gene for inducible nitric oxide synthase. Lab. Invest. 80, 1721\u20131728 (2000).","journal-title":"Lab. Invest."},{"key":"BFnrurol201024_CR66","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s004670200004","volume":"17","author":"H Trachtman","year":"2002","unstructured":"Trachtman, H., Futterweit, S., Pine, E., Mann, J. & Valderrama, E. Chronic diabetic nephropathy: role of inducible nitric oxide synthase. Pediatr. Nephrol. 17, 20\u201329 (2002).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrurol201024_CR67","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.bbrc.2004.10.202","volume":"326","author":"Y Chen","year":"2005","unstructured":"Chen, Y. et al. Deficiency of inducible nitric oxide synthase exacerbates hepatic fibrosis in mice fed high-fat diet. Biochem. Biophys. Res. Commun. 326, 45\u201351 (2005).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BFnrurol201024_CR68","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1002\/hep.22278","volume":"47","author":"G Aram","year":"2008","unstructured":"Aram, G., Potter, J. J., Liu, X., Torbenson, M. S. & Mezey, E. Lack of inducible nitric oxide synthase leads to increased hepatic apoptosis and decreased fibrosis in mice after chronic carbon tetrachloride administration. Hepatology 47, 2051\u20132058 (2008).","journal-title":"Hepatology"},{"key":"BFnrurol201024_CR69","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/sj.jcbfm.9600068","volume":"25","author":"H Bayir","year":"2005","unstructured":"Bayir, H. et al. Enhanced oxidative stress in iNOS deficient mice after traumatic brain injury: support for a neuroprotective role of iNOS. J. Cereb. Blood Flow Metab. 25, 673\u2013684 (2005).","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"BFnrurol201024_CR70","doi-asserted-by":"publisher","first-page":"27256","DOI":"10.1074\/jbc.M301778200","volume":"278","author":"KM Park","year":"2003","unstructured":"Park, K. M. et al. Inducible nitric-oxide synthase is an important contributor to prolonged protective effects of ischemic preconditioning in the mouse kidney. J. Biol. Chem. 278, 27256\u201327266 (2003).","journal-title":"J. Biol. Chem."},{"key":"BFnrurol201024_CR71","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.yjmcc.2005.09.011","volume":"40","author":"SP Jones","year":"2006","unstructured":"Jones, S. P. & Bolli, R. The ubiquitous role of nitric oxide in cardioprotection. J. Mol. Cell. Cardiol. 40, 16\u201323 (2006).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"BFnrurol201024_CR72","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/S0002-9440(10)64607-X","volume":"157","author":"M Hesse","year":"2000","unstructured":"Hesse, M., Cheever, A. W., Jankovic, D. & Wynn, T. A. NOS-2 mediates the protective anti-inflammatory and antifibrotic effects of the Th1-inducing adjuvant, IL-12, in a Th2 model 0f granulomatous disease. Am. J. Pathol. 157, 945\u2013955 (2000).","journal-title":"Am. J. Pathol."},{"key":"BFnrurol201024_CR73","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1161\/01.RES.0000264081.78659.45","volume":"100","author":"P Zhang","year":"2007","unstructured":"Zhang, P. et al. Inducible nitric oxide synthase deficiency protects the heart from systolic overload-induced ventricular hypertrophy and congestive heart failure. Circ. Res. 100, 1089\u20131098 (2007).","journal-title":"Circ. Res."},{"key":"BFnrurol201024_CR74","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/MAJ.0b013e3181571f97","volume":"335","author":"L Lu","year":"2008","unstructured":"Lu, L., Chen, S. S., Hassid, A. & Sun, Y. Cardiac fibrogenesis following infarction in mice with deletion of inducible nitric oxide synthase. Am. J. Med. Sci. 335, 431\u2013438 (2008).","journal-title":"Am. J. Med. Sci."},{"key":"BFnrurol201024_CR75","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1016\/j.transproceed.2009.07.014","volume":"41","author":"M Kadkhodaee","year":"2009","unstructured":"Kadkhodaee, M. et al. Proteinuria is reduced by inhibition of inducible nitric oxide synthase in rat renal ischemia-reperfusion injury. Transplant. Proc. 41, 2907\u20132909 (2009).","journal-title":"Transplant. Proc."},{"key":"BFnrurol201024_CR76","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1161\/01.CIR.103.25.3099","volume":"103","author":"PJ Kuhlencordt","year":"2001","unstructured":"Kuhlencordt, P. J., Chen, J., Han, F., Astern, J. & Huang, P. L. Genetic deficiency of inducible nitric oxide synthase reduces atherosclerosis and lowers plasma lipid peroxides in apolipoprotein E-knockout mice. Circulation 103, 3099\u20133104 (2001).","journal-title":"Circulation"},{"key":"BFnrurol201024_CR77","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1093\/ndt\/gfp103","volume":"24","author":"JE Toblli","year":"2009","unstructured":"Toblli, J. E. et al. Antifibrotic effects of pioglitazone on the kidney in a rat model of type 2 diabetes mellitus. Nephrol. Dial. Transplant. 24, 2384\u20132391 (2009).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrurol201024_CR78","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1096\/fj.08-120857","volume":"23","author":"I Mookerjee","year":"2009","unstructured":"Mookerjee, I. et al. Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2. FASEB J. 23, 1219\u20131229 (2009).","journal-title":"FASEB J."},{"key":"BFnrurol201024_CR79","doi-asserted-by":"publisher","first-page":"L212","DOI":"10.1152\/ajplung.00475.2006","volume":"293","author":"S Vyas-Read","year":"2007","unstructured":"Vyas-Read, S., Shaul, P. W., Yuhanna, I. S. & Willis, B. C. Nitric oxide attenuates epithelial-mesenchymal transition in alveolar epithelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 293, L212\u2013L221 (2007).","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"BFnrurol201024_CR80","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s11154-008-9100-6","volume":"9","author":"FC Brosius 3rd.","year":"2008","unstructured":"Brosius, F. C. 3rd. New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy. Rev. Endocr. Metab. Disord. 9, 245\u2013254 (2008).","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"BFnrurol201024_CR81","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1139\/Y08-047","volume":"86","author":"P Kalk","year":"2008","unstructured":"Kalk, P. et al. Pulmonary fibrosis in L-NAME-treated mice is dependent on an activated endothelin system. Can. J. Physiol. Pharmacol. 86, 541\u2013545 (2008).","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"BFnrurol201024_CR82","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1046\/j.1523-1755.2003.00112.x","volume":"64","author":"H Peters","year":"2003","unstructured":"Peters, H. et al. NO mediates antifibrotic actions of L-arginine supplementation following induction of anti-thy1 glomerulonephritis. Kidney Int. 64, 509\u2013518 (2003).","journal-title":"Kidney Int."},{"key":"BFnrurol201024_CR83","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejphar.2007.06.036","volume":"572","author":"TR Dunkern","year":"2007","unstructured":"Dunkern, T. R., Feurstein, D., Rossi, G. A., Sabatini, F. & Hatzelmann, A. Inhibition of TGF-\u03b2 induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase. Eur. J. Pharmacol. 572, 12\u201322 (2007).","journal-title":"Eur. J. Pharmacol."},{"key":"BFnrurol201024_CR84","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/hr.2009.64","volume":"32","author":"H Masuyama","year":"2009","unstructured":"Masuyama, H. et al. Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart. Hypertens. Res. 32, 597\u2013603 (2009).","journal-title":"Hypertens. Res."},{"key":"BFnrurol201024_CR85","doi-asserted-by":"publisher","first-page":"6018","DOI":"10.1128\/MCB.00225-09","volume":"29","author":"N Sawada","year":"2009","unstructured":"Sawada, N. et al. Cyclic GMP kinase and RhoA Ser188 phosphorylation integrate pro- and anti-fibrotic signals in blood vessels. Mol. Cell. Biol. 29, 6018\u20136032 (2009).","journal-title":"Mol. Cell. Biol."},{"key":"BFnrurol201024_CR86","first-page":"71","volume":"58","author":"A Knorr","year":"2008","unstructured":"Knorr, A. et al. Nitric oxide-independent activation of soluble guanylate cyclase by BAY 60\u20132770 in experimental liver fibrosis. Arzneimittelforschung 58, 71\u201380 (2008).","journal-title":"Arzneimittelforschung"},{"key":"BFnrurol201024_CR87","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.2174\/092986708784567725","volume":"15","author":"Y Wang-Rosenke","year":"2008","unstructured":"Wang-Rosenke, Y., Neumayer, H. H. & Peters, H. NO signaling through cGMP in renal tissue fibrosis and beyond: key pathway and novel therapeutic target. Curr. Med. Chem. 15, 1396\u20131406 (2008).","journal-title":"Curr. Med. Chem."},{"key":"BFnrurol201024_CR88","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1159\/000127335","volume":"80","author":"F Iacono","year":"2008","unstructured":"Iacono, F. et al. Histopathologically proven prevention of post-prostatectomy cavernosal fibrosis with sildenafil. Urol. Int. 80, 249\u2013252 (2008).","journal-title":"Urol. Int."},{"key":"BFnrurol201024_CR89","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/sj.ijir.3901596","volume":"20","author":"L Vignozzi","year":"2008","unstructured":"Vignozzi, L. et al. Effect of sildenafil administration on penile hypoxia induced by cavernous neurotomy in the rat. Int. J. Impot. Res. 20, 60\u201367 (2008).","journal-title":"Int. J. Impot. Res."},{"key":"BFnrurol201024_CR90","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nrurol.2009.126","volume":"6","author":"A Magheli","year":"2009","unstructured":"Magheli, A. & Burnett, A. L. Erectile dysfunction following prostatectomy: prevention and treatment. Nat. Rev. Urol. 6, 415\u2013427 (2009).","journal-title":"Nat. Rev. Urol."},{"key":"BFnrurol201024_CR91","doi-asserted-by":"publisher","first-page":"L24","DOI":"10.1152\/ajplung.00245.2007","volume":"294","author":"AR Hemnes","year":"2008","unstructured":"Hemnes, A. R., Zaiman, A. & Champion, H. C. PDE 5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA\/Rho kinase activation. Am. J. Physiol. Lung Cell. Mol. Physiol. 294, L24\u2013L33 (2008).","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"BFnrurol201024_CR92","doi-asserted-by":"publisher","first-page":"F167","DOI":"10.1152\/ajprenal.00197.2005","volume":"290","author":"Y Wang","year":"2006","unstructured":"Wang, Y. et al. Enhancing cGMP in experimental progressive renal fibrosis: soluble guanylate cyclase stimulation vs. phosphodiesterase inhibition. Am. J. Physiol. Renal Physiol. 290, F167\u2013F176 (2006).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"BFnrurol201024_CR93","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jacc.2008.08.069","volume":"53","author":"T Nagayama","year":"2009","unstructured":"Nagayama, T. et al. Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload. J. Am. Coll. Cardiol. 53, 207\u2013215 (2009).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrurol201024_CR94","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1111\/j.1476-5381.2008.00098.x","volume":"156","author":"T Radovits","year":"2009","unstructured":"Radovits, T. et al. The phosphodiesterase-5 inhibitor vardenafil improves cardiovascular dysfunction in experimental diabetes mellitus. Br. J. Pharmacol. 156, 909\u2013919 (2009).","journal-title":"Br. J. Pharmacol."},{"key":"BFnrurol201024_CR95","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.1093\/ndt\/gfn319","volume":"23","author":"B Hohenstein","year":"2008","unstructured":"Hohenstein, B., Daniel, C., Wittmann, S. & Hugo, C. PDE-5 inhibition impedes TSP-1 expression, TGF-\u03b2 activation and matrix accumulation in experimental glomerulonephritis. Nephrol. Dial. Transplant. 23, 3427\u20133436 (2008).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrurol201024_CR96","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2174\/157488408783329887","volume":"3","author":"P Steiropoulos","year":"2008","unstructured":"Steiropoulos, P., Trakada, G. & Bouros, D. Current pharmacological treatment of pulmonary arterial hypertension. Curr. Clin. Pharmacol. 3, 11\u201319 (2008).","journal-title":"Curr. Clin. Pharmacol."},{"key":"BFnrurol201024_CR97","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/sj.ijir.3900912","volume":"14","author":"LA Levine","year":"2002","unstructured":"Levine, L. A. & Latchamsetty, K. C. Treatment of erectile dysfunction in patients with Peyronie's disease using sildenafil citrate. Int. J. Impot. Res. 14, 478\u2013482 (2002).","journal-title":"Int. J. Impot. Res."},{"key":"BFnrurol201024_CR98","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1111\/j.1743-6109.2008.00935.x","volume":"5","author":"H Porst","year":"2008","unstructured":"Porst, H. et al. Long-term safety and efficacy of tadalafil 5\u00a0mg dosed once daily in men with erectile dysfunction. J. Sex. Med. 5, 2160\u20132169 (2008).","journal-title":"J. Sex. Med."},{"key":"BFnrurol201024_CR99","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.eururo.2007.06.048","volume":"52","author":"AJ Bella","year":"2007","unstructured":"Bella, A. J., Deyoung, L. X., Al-Numi, M. & Brock, G. B. Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications. Eur. Urol. 52, 990\u20131005 (2007).","journal-title":"Eur. Urol."}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrurol.2010.24.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrurol.2010.24","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrurol.2010.24.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,24]],"date-time":"2024-03-24T18:55:52Z","timestamp":1711306552000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrurol.2010.24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,9]]},"references-count":99,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["BFnrurol201024"],"URL":"https:\/\/doi.org\/10.1038\/nrurol.2010.24","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,9]]}}}